StockData
Perspective Therapeutics, Inc. logo

Perspective Therapeutics, Inc. (CATX) stock

CATXNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/30
$0.75−0.03 (-3.85%)

Close on Nov 20, 2026Market cap $86.05MP/E –Yield –

Perspective Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Perspective Therapeutics's price to sales ratio was 22.2× on Jan 31, 2025, against 10.7× a year earlier. Over the last 5 years it ranged from 2.6× to 98.7×, with a median of 6.0×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2025Jan 31, 202522.2×+2.3
2024Dec 31, 202420.0×+14.7
2023Dec 29, 20235.3×+2.0
2022Dec 30, 20223.3×−2.1
2021Dec 31, 20215.4×+2.2
2020Dec 31, 20203.2×−2.0
2019Dec 31, 20195.2×+2.0
2018Dec 31, 20183.2×−1.3
2017Dec 29, 20174.5×−2.5
2016Dec 30, 20167.0×−3.8
2015Dec 31, 201510.7×−8.3
2014Dec 31, 201419.0×+14.8
2013Dec 31, 20134.3×−1.2
2012Dec 31, 20125.5×+2.1
2011Dec 30, 20113.4×–

More Perspective Therapeutics figures

See a number that looks wrong?